Perrigo Claims Reckitt's Bid To Block Generic Mucinex Is "Baseless"
This article was originally published in The Tan Sheet
Executive Summary
Reckitt Benckiser's petition seeking to define specific bioequivalence standards for private-label versions of Mucinex OTC cough products, if followed, would push FDA to violate generic drug law, Perrigo argues
You may also be interested in...
FDA Denial Of Mucinex Petition Stops Reckitt's Bid To Delay Generics
FDA stymies Reckitt Benckiser's attempt to delay private label competition for Mucinex OTC cough products by rejecting the firm's request to redefine bioequivalence standards for guaifenesin generics
Reckitt Bids To Delay Mucinex Competition With Bioequivalance Petition
In an attempt to delay private-label competition for Mucinex OTC cough products, Reckitt Benckiser asks FDA to ensure potential generics meet the same bioequivalence across the 12-hour dosing interval as the branded product
Watson Files ANDA For Mucinex DM, Gets In Line For Generic Guaifenesin
Watson Pharmaceuticals appears to be the first firm to file an abbreviated new drug application with FDA to market a private label version of Reckitt Benckiser's Mucinex DM